Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Obesity With Diabetes, Overweight With Diabetes

In brief

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

Key facts

Study ID
NCT07284901
Run by
Kailera
People needed
1156
Starts
2026-01-12
Expected to finish
2028-04-24
Last updated by the study team
2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.